Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia

E. Waanders; V.H.J. van der Velden; C.E. van der Schoot; F.N. van Leeuwen; S.V. van Reijmersdal; V. de Haas; A.J.P. Veerman; A.G. van Kessel; PM Hoogerbrugge; R.P. Kuiper; J.J.M. van Dongen

doi:10.1038/leu.2010.275

Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia

E. Waanders, V.H.J. van der Velden, C.E. van der Schoot, F.N. van Leeuwen, S.V. van Reijmersdal, V. de Haas, A.J.P. Veerman, A.G. van Kessel, PM Hoogerbrugge, R.P. Kuiper, J.J.M. van Dongen

Pediatrics

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	254-258
Journal	Leukemia
Volume	25
Issue number	2
DOIs	https://doi.org/10.1038/leu.2010.275
Publication status	Published - 2011

Access to Document

10.1038/leu.2010.275

Cite this

Waanders, E., van der Velden, V. H. J., van der Schoot, C. E., van Leeuwen, F. N., van Reijmersdal, S. V., de Haas, V., Veerman, A. J. P., van Kessel, A. G., Hoogerbrugge, PM., Kuiper, R. P., & van Dongen, J. J. M. (2011). Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia. Leukemia, 25(2), 254-258. https://doi.org/10.1038/leu.2010.275

Waanders, E. ; van der Velden, V.H.J. ; van der Schoot, C.E. ; van Leeuwen, F.N. ; van Reijmersdal, S.V. ; de Haas, V. ; Veerman, A.J.P. ; van Kessel, A.G. ; Hoogerbrugge, PM ; Kuiper, R.P. ; van Dongen, J.J.M. / Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia. In: Leukemia. 2011 ; Vol. 25, No. 2. pp. 254-258.

@article{718dadd315804f92b5fa856ba6908d2d,

title = "Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia",

author = "E. Waanders and {van der Velden}, V.H.J. and {van der Schoot}, C.E. and {van Leeuwen}, F.N. and {van Reijmersdal}, S.V. and {de Haas}, V. and A.J.P. Veerman and {van Kessel}, A.G. and PM Hoogerbrugge and R.P. Kuiper and {van Dongen}, J.J.M.",

year = "2011",

doi = "10.1038/leu.2010.275",

language = "Undefined/Unknown",

volume = "25",

pages = "254--258",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "2",

}

Waanders, E, van der Velden, VHJ, van der Schoot, CE, van Leeuwen, FN, van Reijmersdal, SV, de Haas, V, Veerman, AJP, van Kessel, AG, Hoogerbrugge, PM, Kuiper, RP & van Dongen, JJM 2011, 'Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia', Leukemia, vol. 25, no. 2, pp. 254-258. https://doi.org/10.1038/leu.2010.275

Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia. / Waanders, E.; van der Velden, V.H.J.; van der Schoot, C.E.; van Leeuwen, F.N.; van Reijmersdal, S.V.; de Haas, V.; Veerman, A.J.P.; van Kessel, A.G.; Hoogerbrugge, PM; Kuiper, R.P.; van Dongen, J.J.M.

In: Leukemia, Vol. 25, No. 2, 2011, p. 254-258.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia

AU - Waanders, E.

AU - van der Velden, V.H.J.

AU - van der Schoot, C.E.

AU - van Leeuwen, F.N.

AU - van Reijmersdal, S.V.

AU - de Haas, V.

AU - Veerman, A.J.P.

AU - van Kessel, A.G.

AU - Hoogerbrugge, PM

AU - Kuiper, R.P.

AU - van Dongen, J.J.M.

PY - 2011

Y1 - 2011

U2 - 10.1038/leu.2010.275

DO - 10.1038/leu.2010.275

M3 - Article

C2 - 21102428

VL - 25

SP - 254

EP - 258

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 2

ER -